192 related articles for article (PubMed ID: 12509619)
1. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes.
Burger D; Begué-Pastor N; Benavent S; Gruaz L; Kaufmann MT; Chicheportiche R; Dayer JM
Rheumatology (Oxford); 2003 Jan; 42(1):89-96. PubMed ID: 12509619
[TBL] [Abstract][Full Text] [Related]
2. Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes.
Vergne-Salle P; Léger DY; Bertin P; Trèves R; Beneytout JL; Liagre B
Cytokine; 2005 Sep; 31(5):335-48. PubMed ID: 16099671
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis.
Cutolo M; Sulli A; Ghiorzo P; Pizzorni C; Craviotto C; Villaggio B
Ann Rheum Dis; 2003 Apr; 62(4):297-302. PubMed ID: 12634225
[TBL] [Abstract][Full Text] [Related]
4. The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha.
Magne D; Mézin F; Palmer G; Guerne PA
Inflamm Res; 2006 Nov; 55(11):469-75. PubMed ID: 17122964
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of cyclooxygenase 2-generated prostaglandin E2 synthesis in rheumatoid arthritis synoviocytes by taurine chloramine.
Kontny E; Rudnicka W; Kowalczewski J; Marcinkiewicz J; Maslinski W
Arthritis Rheum; 2003 Jun; 48(6):1551-5. PubMed ID: 12794822
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2-derived E prostaglandins down-regulate matrix metalloproteinase-1 expression in fibroblast-like synoviocytes via inhibition of extracellular signal-regulated kinase activation.
Pillinger MH; Rosenthal PB; Tolani SN; Apsel B; Dinsell V; Greenberg J; Chan ES; Gomez PF; Abramson SB
J Immunol; 2003 Dec; 171(11):6080-9. PubMed ID: 14634122
[TBL] [Abstract][Full Text] [Related]
7. Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1beta stimulated rheumatoid synovial fibroblasts.
Migita K; Miyashita T; Ishibashi H; Maeda Y; Nakamura M; Yatsuhashi H; Ida H; Kawakami A; Aoyagi T; Kawabe Y; Eguchi K
Clin Exp Immunol; 2004 Sep; 137(3):612-6. PubMed ID: 15320915
[TBL] [Abstract][Full Text] [Related]
8. The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes.
Palmer G; Burger D; Mezin F; Magne D; Gabay C; Dayer JM; Guerne PA
Arthritis Res Ther; 2004; 6(3):R181-9. PubMed ID: 15142263
[TBL] [Abstract][Full Text] [Related]
9. The effects of 1 alpha,25-dihydroxyvitamin D(3) on matrix metalloproteinase and prostaglandin E(2) production by cells of the rheumatoid lesion.
Tetlow LC; Woolley DE
Arthritis Res; 1999; 1(1):63-70. PubMed ID: 11056661
[TBL] [Abstract][Full Text] [Related]
10. Triptolide, a novel diterpenoid triepoxide from Tripterygium wilfordii Hook. f., suppresses the production and gene expression of pro-matrix metalloproteinases 1 and 3 and augments those of tissue inhibitors of metalloproteinases 1 and 2 in human synovial fibroblasts.
Lin N; Sato T; Ito A
Arthritis Rheum; 2001 Sep; 44(9):2193-200. PubMed ID: 11592385
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate and cyclooxygenase metabolism in cultured human rheumatoid synoviocytes.
Vergne P; Liagre B; Bertin P; Cook-Moreau J; Treves R; Beneytout JL; Rigaud M
J Rheumatol; 1998 Mar; 25(3):433-40. PubMed ID: 9517759
[TBL] [Abstract][Full Text] [Related]
12. Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: involvement of membrane-associated cytokines.
Burger D; Rezzonico R; Li JM; Modoux C; Pierce RA; Welgus HG; Dayer JM
Arthritis Rheum; 1998 Oct; 41(10):1748-59. PubMed ID: 9778216
[TBL] [Abstract][Full Text] [Related]
13. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner.
Hamilton LC; Vojnovic I; Warner TD
Br J Pharmacol; 1999 Aug; 127(7):1589-96. PubMed ID: 10455314
[TBL] [Abstract][Full Text] [Related]
14. Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures.
Elkayam O; Yaron I; Shirazi I; Judovitch R; Caspi D; Yaron M
Ann Rheum Dis; 2003 May; 62(5):440-3. PubMed ID: 12695157
[TBL] [Abstract][Full Text] [Related]
15. The active form of leflunomide, HMR1726, facilitates TNF-alpha and IL-17 induced MMP-1 and MMP-3 expression.
Alexander D; Friedrich B; Abruzzese T; Gondolph-Zink B; Wülker N; Aicher WK
Cell Physiol Biochem; 2006; 17(1-2):69-78. PubMed ID: 16543723
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts.
Kojima F; Naraba H; Sasaki Y; Beppu M; Aoki H; Kawai S
Arthritis Rheum; 2003 Oct; 48(10):2819-28. PubMed ID: 14558087
[TBL] [Abstract][Full Text] [Related]
17. The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
Moon SJ; Kim EK; Jhun JY; Lee HJ; Lee WS; Park SH; Cho ML; Min JK
J Transl Med; 2017 Feb; 15(1):31. PubMed ID: 28193225
[TBL] [Abstract][Full Text] [Related]
18. An active metabolite of leflunomide, A77 1726, inhibits the production of serum amyloid A protein in human hepatocytes.
Migita K; Miyashita T; Maeda Y; Nakamura M; Yatsuhashi H; Ishibashi H; Eguchi K
Rheumatology (Oxford); 2005 Apr; 44(4):443-8. PubMed ID: 15695308
[TBL] [Abstract][Full Text] [Related]
19. Activation of synovial cell p38 MAP kinase by macrophage migration inhibitory factor.
Santos LL; Lacey D; Yang Y; Leech M; Morand EF
J Rheumatol; 2004 Jun; 31(6):1038-43. PubMed ID: 15170913
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
